These findings indicate the potential of exenatide, curcumin, tRES-HESP and bromocriptine-QR in mitigating oxidative and inflammatory stress pathways in T2DM patients and individuals with obesity, via the modulation of NRF2-related genes. The gene discussed is TMPRSS11A; the disease is obesity due to melanocortin 4 receptor deficiency.